Dr. Michael Z. Kharouta, MD

Dr. Kharouta practices at Advocate Illinois Masonic Medical Center in Chicago, Illinois, part of Advocate Health.

Dr. Kharouta's NPI, 1336670322, was assigned on March 22, 2017. Dr. Kharouta graduated from Rush Medical College of Rush University in 2017. Dr. Kharouta holds Illinois license 036159163.

Dr. Kharouta's primary practice is Advocate Illinois Masonic Medical Center, at 836 West Wellington Avenue, Chicago, IL 60657 in Cook County. The practice phone is (773) 975-1600.

Dr. Kharouta's primary practice is Advocate Illinois Masonic Medical Center in Chicago, Illinois, part of Advocate Health. Dr. Kharouta is also affiliated with Advocate Lutheran General Hospital. The medical group on file is Northwestern Medical Faculty Foundation. Dmand AI also links Dr. Kharouta to 3 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kharouta practices, 7 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Kharouta's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Kharouta is licensed in Illinois.

CMS data shows 1,041 Medicare services from Dr. Kharouta across 14 procedure codes in 2024, for 209 Medicare patients. Medicare paid $87,611 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 209 Medicare patients who saw Dr. Kharouta in 2024. The largest group is 65 to 74, with 109 patients. 75% of them have cancer, and 75% have high blood pressure. 19% are also on Medicaid. Their average risk score is 1.69, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kharouta's median patient age at 69, with 61% women.

In 2024, Dr. Kharouta wrote 158 Medicare Part D claims for 66 patients. 93% of them were for generic drugs. CMS names the drug for 58 of them, across 3 drugs with 11 or more claims each, at $867 in total drug cost. In 2023, CMS named 13 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 95 out of 100 for Dr. Kharouta for performance year 2024, reported through an alternative payment model (APM). Dr. Kharouta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kharouta as offering telehealth.

Dmand AI links 24 papers to Dr. Kharouta, published from 2013 to 2025. 2022 was the busiest year, with 6. The most frequent topics are Brachytherapy, Breast Neoplasms and Lung Neoplasms. Dr. Kharouta has published most often in Adv Radiat Oncol. Dr. Kharouta's most frequent co-authors are Mitchell Machtay, MD, Aashish D. Bhatt, MD and Serah Choi, MD, PhD.

CMS Open Payments shows 39 general payments to Dr. Kharouta from 9 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 63% of the total. Teleflex LLC paid the most, $3,239.

Dr. Kharouta graduated from Rush Medical College of Rush University in 2017.